The FDA-approved indications for GLP-1 weight loss medications (Wegovy, Zepbound) require a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity. These are the eligibility thresholds that licensed telehealth providers — including Luma Health — use to evaluate patients before prescribing.
Below a BMI of 27, GLP-1 prescribing for weight loss would require off-label use, which is legal for physicians but carries different clinical and regulatory considerations. This guide explains exactly who qualifies under standard criteria, what the lower BMI threshold (27 + comorbidity) means in practice, how off-label prescribing works legally, and what patients below standard thresholds should know before pursuing treatment.
The FDA Eligibility Criteria: What They Say and Why They Exist
The FDA approved semaglutide (Wegovy) for chronic weight management in June 2021, and tirzepatide (Zepbound) in November 2023. Both approvals came with specific eligibility criteria derived from the clinical trial populations in which the medications demonstrated safety and efficacy. Understanding these criteria — and the rationale behind them — is essential for patients trying to determine whether they qualify.
For both Wegovy and Zepbound, the FDA-approved indications for adults are identical in structure: a body mass index (BMI) of 30 kg/m² or greater (classified as obesity), or a BMI of 27 kg/m² or greater in the presence of at least one weight-related comorbidity. The term "weight-related comorbidity" has a specific clinical meaning in this context — it refers to conditions that are causally or meaningfully associated with excess body weight, such that weight loss is expected to improve or resolve them.
The BMI thresholds were chosen because the large-scale clinical trials — STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide — enrolled participants who met these criteria. The safety and efficacy data that supported FDA approval are derived from those populations. Patients outside those parameters were not studied at scale, which is why the FDA's approved indication is bounded by them.
The lower threshold of BMI 27 with comorbidity reflects an important clinical reality: excess weight at BMI levels well below 30 can carry meaningful health risk when metabolic comorbidities are present. A patient with a BMI of 28 and type 2 diabetes, hypertension, and sleep apnea has a weight-related disease burden that is clinically significant regardless of where their number falls relative to the 30-point obesity threshold. The FDA's dual threshold acknowledges this nuance.
What BMI Actually Measures — and Its Limitations
Body mass index is a population-level screening tool, not a direct measure of adiposity or metabolic health. It is calculated by dividing body weight in kilograms by height in meters squared (kg/m²). At a population level, BMI correlates reasonably well with excess adiposity and associated health risk. At the individual level, BMI has well-documented limitations: it does not distinguish between lean mass and fat mass, does not account for fat distribution (visceral vs. subcutaneous), and systematically underestimates health risk in certain populations (particularly Asian and South Asian patients, where metabolic risk increases at lower BMI values) while sometimes overestimating risk in others (muscular individuals).
The AACE/ACE 2016 clinical practice guidelines for obesity acknowledge these limitations and recommend that clinicians use BMI as a starting point, not an endpoint, for clinical evaluation. A patient with a BMI of 26.5 but significant central adiposity, insulin resistance, and prediabetes may have a greater clinical benefit from GLP-1 treatment than a patient with a BMI of 31 but no metabolic comorbidities. This is the context in which off-label GLP-1 prescribing at lower BMI levels must be understood.
Who Qualifies Under Standard FDA Criteria
Before discussing the more complex territory of lower BMI prescribing, it is worth being precise about the standard eligibility framework. Many patients who believe they do not qualify under FDA criteria actually do qualify under the BMI 27 + comorbidity pathway — and are not aware that this lower threshold exists.
✅ Clearly Qualifies
- ● BMI ≥30 with no comorbidities
- ● BMI ≥30 with one or more comorbidities
- ● BMI ≥27 with type 2 diabetes
- ● BMI ≥27 with hypertension
- ● BMI ≥27 with dyslipidemia (high cholesterol or triglycerides)
- ● BMI ≥27 with obstructive sleep apnea
- ● BMI ≥27 with cardiovascular disease
⚠ Requires Clinical Assessment
- ● BMI 25–26.9 with metabolic comorbidities (off-label territory)
- ● BMI ≥27 with prediabetes (comorbidity status debated)
- ● BMI ≥27 with PCOS (comorbidity status varies by provider)
- ● BMI ≥27 with non-alcoholic fatty liver disease (NAFLD)
- ● BMI ≥27 with osteoarthritis significantly worsened by weight
- ● Asian or South Asian patients with lower BMI but high metabolic risk
The Five Standard Weight-Related Comorbidities
The FDA's prescribing information for both Wegovy and Zepbound identifies weight-related comorbidities that qualify patients with BMI ≥27 for treatment. These five conditions are the clearest pathways for patients who fall below the BMI 30 threshold.
Type 2 Diabetes
The most common qualifying comorbidity. GLP-1 medications were originally developed for T2D and have strong evidence for glycemic benefit alongside weight loss.
Hypertension
Elevated blood pressure caused or worsened by excess weight. Weight loss of 5–10% is associated with meaningful blood pressure reduction in most patients.
Dyslipidemia
Elevated LDL, low HDL, or elevated triglycerides causally associated with excess weight. Tirzepatide has particularly strong evidence for lipid improvement.
Sleep Apnea
Obstructive sleep apnea strongly associated with excess adiposity, particularly central fat distribution. Weight loss of 10–15% is associated with significant improvement or resolution.
Cardiovascular Disease
The SELECT trial (NEJM 2023) demonstrated semaglutide reducing major cardiovascular events by 20% in patients with established cardiovascular disease and overweight/obesity.
Other Conditions
Prediabetes, PCOS, NAFLD, and osteoarthritis are clinically relevant but not explicitly named in FDA labeling. Provider discretion applies to these cases.
Off-Label Prescribing: What It Means and How It Works
Off-label prescribing refers to a physician prescribing an FDA-approved medication for an indication, patient population, dosage, or route of administration that is outside the specific language of the FDA's approved labeling. It is legal, common, and in many clinical contexts, evidence-based. The FDA explicitly acknowledges that off-label prescribing is part of the practice of medicine and does not regulate how physicians prescribe approved drugs to individual patients — only the marketing claims manufacturers can make.
According to a 2006 JAMA study, approximately 21% of all prescriptions written in the United States are for off-label purposes. For certain drug categories — particularly psychiatry, oncology, and pediatrics — off-label prescribing rates are substantially higher. A physician who believes that a GLP-1 medication is clinically appropriate for a patient with a BMI below 27 can legally prescribe it, provided they can articulate a reasonable clinical rationale and have properly informed the patient of the off-label nature of the prescription.
What off-label prescribing does not mean is that the medication is experimental, unproven, or unsafe. It means that the FDA has not reviewed and approved data specifically for that indication — often because a clinical trial in that specific population has not been submitted. There is emerging evidence for GLP-1 use in lower-BMI populations, including in patients with prediabetes and metabolic syndrome at BMI levels below 27, though it has not reached the threshold for formal FDA indication expansion as of 2026.
The BMI 27 Threshold in Practice: What Counts as a Comorbidity?
For patients with a BMI between 27 and 29.9, the key clinical question is whether they have a qualifying weight-related comorbidity. This determination is not always straightforward, and different clinicians may approach borderline cases differently. Understanding which conditions are most clearly recognized and which are more contested helps patients enter the intake process with accurate expectations.
| Condition | Explicitly Named in FDA Labeling? | Strength of Weight-Link Evidence | Typical Clinical Approach |
|---|---|---|---|
| Type 2 diabetes | Yes | Very strong | Always qualifies at BMI ≥27 |
| Hypertension | Yes | Very strong | Always qualifies at BMI ≥27 |
| Dyslipidemia | Yes | Very strong | Always qualifies at BMI ≥27 |
| Obstructive sleep apnea | Yes | Very strong | Always qualifies at BMI ≥27 |
| Cardiovascular disease | Yes | Very strong (SELECT trial) | Always qualifies at BMI ≥27 |
| Prediabetes / insulin resistance | Not explicitly | Strong | Provider discretion — many consider it qualifying |
| PCOS | Not explicitly | Moderate-strong | Provider discretion — often considered qualifying |
| Non-alcoholic fatty liver disease | Not explicitly | Strong (emerging evidence) | Provider discretion — increasingly recognized |
| Osteoarthritis (weight-aggravated) | Not explicitly | Moderate | Case-by-case clinical judgment |
| Depression (weight-related) | Not explicitly | Moderate | Rarely considered qualifying alone |
The most important takeaway from this table is that patients with prediabetes, PCOS, or NAFLD at BMI 27–29.9 occupy clinical territory where provider judgment is the determining factor. These conditions are weight-related and respond to weight loss, but the FDA labeling does not name them explicitly. A clinician who believes the risk-benefit profile supports GLP-1 prescribing in these patients can make that determination in the context of an individual clinical assessment. A clinician who applies only the five named comorbidities strictly may not prescribe in the same cases.
Special Populations: Lower BMI Thresholds for Asian Patients
One of the most clinically important nuances in GLP-1 eligibility is the well-established lower metabolic risk threshold in Asian and South Asian populations. Multiple professional organizations — including the American Diabetes Association, the World Health Organization, and the American Association of Clinical Endocrinology — have issued guidance recognizing that metabolic risk (insulin resistance, type 2 diabetes, cardiovascular disease) increases at substantially lower BMI levels in Asian patients compared to the general population used to calibrate standard BMI cutoffs.
The ADA's 2023 Standards of Medical Care in Diabetes recommends screening for type 2 diabetes in Asian American patients starting at a BMI of 23 — well below the standard 25 overweight threshold. This reflects the documented reality that visceral adiposity accumulates at lower body weight in these populations, producing metabolic consequences at BMI levels that would be categorized as normal weight using standard references.
In clinical practice, this means that an Asian patient with a BMI of 25 and documented insulin resistance, prediabetes, or metabolic syndrome may have a clinically well-founded basis for GLP-1 treatment that a standard BMI-based eligibility algorithm would not capture. The clinical assessment of an individual patient — including their ethnicity, body composition, metabolic markers, and family history — is more relevant than a single BMI number in these cases. Patients in this situation should present this context explicitly during their provider intake.
What Luma Health's Eligibility Process Looks Like
At Luma Health, eligibility is determined by a licensed clinician from Wasef Health, PC who reviews each patient's intake individually. The standard eligibility criteria used are FDA-aligned: BMI of 30 or greater, or BMI of 27 or greater with at least one qualifying weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).
Patients whose BMI falls below the standard thresholds but who have clinically significant metabolic conditions — prediabetes, PCOS, NAFLD, or documented insulin resistance — are encouraged to include this information in their intake and to flag it explicitly. The clinical provider reviews each case individually and may request additional information about medical history, current medications, or recent lab values to inform the prescribing decision. This is a clinical judgment, not an automated algorithm.
Luma Health does not guarantee prescriptions for patients who fall outside standard FDA eligibility thresholds, and our clinical team does not prescribe for cosmetic or convenience purposes at BMI levels below 27 without a clinical rationale. This reflects both responsible clinical practice and our commitment to patient safety — not a restriction designed to limit access to clinically appropriate care.
Complete the intake honestly and completely
Include all relevant medical history, current conditions, medications, and labs. If you have prediabetes, PCOS, NAFLD, insulin resistance, or significant cardiovascular risk markers at a BMI below 30, include these explicitly. The intake form is a clinical document, not a marketing questionnaire — the more complete and accurate your information, the better the clinical review can serve you.
Provide supporting documentation when relevant
If you have recent lab results showing prediabetes (HbA1c 5.7–6.4%), elevated fasting glucose, or lipid abnormalities, including these in your intake strengthens the clinical picture. Patients at borderline BMI levels benefit from having objective metabolic data that supports the clinical rationale for treatment. If you have a primary care provider who has recommended GLP-1 consideration, noting this is also relevant.
Understand that eligibility is a clinical determination
The Luma Health provider who reviews your intake makes a clinical judgment about whether GLP-1 treatment is appropriate for you — including whether the risk-benefit profile is favorable at your specific BMI and health profile. If you are not approved, the provider will explain why. If you are in a borderline category, the conversation with your provider is the right venue for discussing your individual circumstances.
If declined, ask about alternative approaches
Patients who do not meet GLP-1 eligibility thresholds may benefit from other interventions for weight and metabolic health — including structured nutrition counseling, metformin for prediabetes, or other medications for specific comorbidities. Your Luma Health provider can discuss what is clinically appropriate for your situation even if GLP-1 medication is not the right fit at this time.
What to Do If Your BMI Is Below 27
Patients with a BMI below 27 who are seeking GLP-1 medication for weight loss face the most complex eligibility landscape. Standard FDA criteria do not support prescribing in this population for weight management, and responsible clinical practice requires a genuine individual assessment rather than routine off-label prescribing for anyone who asks.
If you have a BMI below 27 and believe you have a metabolic condition that might support GLP-1 consideration, the most productive path is to work with a primary care physician or endocrinologist who can evaluate your complete metabolic profile — including body composition, visceral fat distribution, glycemic markers, lipid profile, blood pressure, and family history — and make a well-documented clinical determination about whether off-label GLP-1 prescribing is appropriate in your specific case. This is a higher standard of clinical evaluation than a telehealth intake form supports, and it is the appropriate standard for off-label prescribing decisions.
Attempting to obtain GLP-1 prescriptions through platforms that apply minimal clinical scrutiny below BMI 27 carries real risks: the medication's safety at lower BMI levels is less well-characterized, the risk-benefit calculation is less favorable when the weight-related disease burden is lower, and providers who prescribe without adequate individual assessment are exposing patients to clinical risk that a proper evaluation might identify as contraindicated.
Frequently Asked Questions
What is the minimum BMI to get GLP-1 medication?
The FDA-approved minimum BMI for GLP-1 weight loss medication (Wegovy, Zepbound) is 27 kg/m², provided the patient also has at least one weight-related comorbidity — type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. For patients without any of these comorbidities, the minimum BMI threshold is 30 kg/m². These are the criteria used by Luma Health and most responsible telehealth providers. Off-label prescribing below a BMI of 27 is legally possible but requires a clinician's documented individual clinical assessment and is not standard practice.
Can I get semaglutide if my BMI is 28 with no other health conditions?
Under current FDA-approved criteria, a BMI of 28 without any qualifying weight-related comorbidity does not meet the standard eligibility threshold — which requires either BMI ≥30 or BMI ≥27 plus a comorbidity. However, if you have any of the five qualifying comorbidities (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease) or clinically significant conditions like prediabetes, PCOS, or NAFLD, your provider may evaluate whether GLP-1 treatment is appropriate in your individual case. The intake process at Luma Health involves a clinical review that considers your full health profile, not just BMI alone.
Does prediabetes count as a comorbidity for GLP-1 eligibility?
Prediabetes is not explicitly named in the FDA prescribing information for Wegovy or Zepbound as a qualifying comorbidity, but it is clinically meaningful and weight-related. Many providers consider prediabetes (defined as HbA1c of 5.7–6.4% or fasting glucose of 100–125 mg/dL) a clinically relevant condition that supports GLP-1 consideration at BMI ≥27, particularly given the strong evidence that GLP-1 medications reduce progression from prediabetes to type 2 diabetes. Whether a specific provider applies this interpretation depends on their clinical judgment and protocol. Including documented prediabetes in your Luma Health intake gives your provider the information needed to make an individual determination.
Can Asian patients qualify for GLP-1 at a lower BMI?
Clinically, yes — and this is increasingly recognized in professional guidelines. Asian and South Asian patients develop metabolic complications (insulin resistance, type 2 diabetes, cardiovascular risk) at lower BMI levels than populations used to calibrate standard Western BMI references. The ADA recommends diabetes screening for Asian Americans starting at BMI 23. While the FDA has not formally adopted different BMI thresholds for Asian patients in GLP-1 labeling, a clinician evaluating an Asian patient with a BMI of 25–26 and documented insulin resistance or prediabetes has a sound clinical basis for off-label GLP-1 consideration. This requires individual clinical assessment — include your ethnicity and metabolic markers explicitly in your intake.
Does PCOS qualify as a comorbidity for GLP-1 at BMI 27?
Polycystic ovary syndrome is a weight-related condition with meaningful metabolic consequences — insulin resistance, dysglycemia, lipid abnormalities, and cardiovascular risk — that often improve with weight loss. While PCOS is not listed by name in FDA GLP-1 labeling as a qualifying comorbidity, many clinicians treat it as functionally equivalent to a metabolic comorbidity given the strength of the weight-PCOS connection and the evidence that GLP-1 medications benefit PCOS patients. Several telehealth providers explicitly include PCOS as a qualifying condition. At Luma Health, your provider reviews your case individually — including PCOS, any associated metabolic markers, and your overall clinical picture — before making a prescribing determination.
Is it safe to get GLP-1 medication with a low BMI?
The safety of GLP-1 medications at lower BMI levels is less extensively studied than in the populations covered by FDA-approved indications. The medications carry the same class-level risks regardless of BMI — gastrointestinal side effects, gallbladder disease, rare pancreatitis risk, and the boxed warning regarding thyroid C-cell tumors in rodents. In lower-weight patients, the practical concerns about adequate nutrition and avoiding excessive weight loss are more clinically significant than in higher-weight patients. The risk-benefit profile that supports GLP-1 prescribing at BMI 30+ or BMI 27+ with comorbidities may not apply equally at lower BMI levels. Any prescribing decision below standard FDA thresholds requires careful individual clinical evaluation — not a streamlined telehealth intake designed for the standard-eligibility population.
Does Luma Health prescribe GLP-1 below BMI 27?
Luma Health uses FDA-aligned eligibility criteria: BMI ≥30, or BMI ≥27 with at least one qualifying weight-related comorbidity. Our clinical providers from Wasef Health, PC review each intake individually and may consider clinically significant conditions like prediabetes, PCOS, or NAFLD at BMI ≥27 in their assessment. For patients with BMI below 27, Luma Health does not routinely prescribe GLP-1 medications for weight loss — this falls outside standard FDA-approved indications and responsible telehealth prescribing practice. Patients in this category are best served by evaluation with a primary care physician or endocrinologist who can conduct a comprehensive metabolic assessment and, if clinically appropriate, consider off-label prescribing with the full individual context that warrants it.
What if I don't know my BMI — how do I calculate it?
BMI is calculated by dividing your weight in kilograms by your height in meters squared. In US customary units, the formula is: (weight in pounds × 703) ÷ (height in inches)². For example, a person who weighs 180 pounds and is 5 feet 7 inches (67 inches) tall has a BMI of approximately (180 × 703) ÷ (67²) = 126,540 ÷ 4,489 ≈ 28.2. Multiple online calculators can perform this calculation instantly. The Luma Health intake form will also calculate your BMI based on the height and weight you provide. What matters for eligibility is not just the number but the combination of that number with your medical history — which is why the clinical intake review is more important than any self-calculation.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PubMed
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232. PubMed
- FDA. Wegovy (semaglutide) Prescribing Information. 2023. FDA.gov
- FDA. Zepbound (tirzepatide) Prescribing Information. 2023. FDA.gov
- American Diabetes Association. Standards of Medical Care in Diabetes 2023 — Classification and Diagnosis of Diabetes. Diabetes Care. 2023;46(Suppl 1):S19–S40. ADA.org
- Garvey WT, et al. AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22(Suppl 3):1–203. Endocrine Practice
- Apovian CM, et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(2):342–362. PubMed
- Radley DC, et al. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021–1026. PubMed
- NIDDK. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov